BI 3000202 drug interaction study with rosuvastatin and digoxin

Phase 1, open-label, single-arm trial of BI 3000202, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity at 7 days, Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity at 7 days and 2 more. Started Nov 2025; status: completed.